No risk of VTE in Eczema Patients Receiving JAK Inhibitors: Study

Results:

• Two cohort studies and 15 RCTs with a total of 466 993 participants were included.
• The meta-analysis found no significant association of atopic dermatitis with incident venous thromboembolism
• Overall, 3 of 5722 patients with atopic dermatitis (0.05%) who were receiving treatment with JAK inhibitors experienced venous thromboembolism compared with 1 of 3065 patients with atopic dermatitis (0.03%) receiving placebo or dupilumab
• The incidence rate of venous thromboembolism was 0.15 and 0.12 events per 100 patient-years in participants with atopic dermatitis receiving JAK inhibitors and placebo, respectively.
• The findings were similar in 4 unique JAK inhibitors

Thus, the results of this systematic review and meta-analysis suggest that the currently available evidence does not detect an increased risk of venous thromboembolism associated with atopic dermatitis or treatment with JAK inhibitors. These findings may provide a reference for clinicians in prescribing JAK inhibitors for patients with atopic dermatitis.

Reference:

Chen T, Lee L, Huang H, Chen L, Loh C, Chi C. Association of Risk of Incident Venous Thromboembolism With Atopic Dermatitis and Treatment With Janus Kinase Inhibitors: A Systematic Review and Meta-analysis. JAMA Dermatol. Published online August 24, 2022. doi:10.1001/jamadermatol.2022.3516

Keywords:

Tai-Li Chen, Ling-Ling Lee, Huei-Kai Huang, Li-Yu Chen, Ching-Hui Loh, Ching-Chi Chi, JAMA Dermatology, Janus Kinase Inhibitors, Risk, Atopic Dermatitis, Association, Treatment